top of page

Astria Therapeutics licensed its HAE treatment, Navenibart, to Kaken Pharmaceutical for the Japanese market. It is a kallikrein inhibitor that is in phase 3, and is dosed up to every six months

  • Aug 7, 2025
  • 1 min read

President and CEO Jill Milne describes what she believes is the unmet need and profile of Navenibart, and walks us through future anticipated developments. Plus, discussing the company's OX40 antagonist for atopic dermatitis that will have key healthy volunteer proof of concept data in the third quarter of this year.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

​

​Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page